Cases & Deals

  • Home
  • Practices
  • Ambrx and Hisun collaborate on development and commercialization of bispecifics for cancer

Share

Ambrx and Hisun collaborate on development and commercialization of bispecifics for cancer

April 2014

Client(s) Ambrx, Inc.

Jones Day represented Ambrx, Inc. in its collaboration with Zhejiang Hisun Pharmaceutical Company Ltd. for the development and commercialization of bispecifics based on Ambrx technology for the treatment of cancer. Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun will manufacture the product to cGMP standards for commercial supplies on a global basis.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.